ATE471371T1 - Antikrebsmittel mit verotoxinvarianten - Google Patents

Antikrebsmittel mit verotoxinvarianten

Info

Publication number
ATE471371T1
ATE471371T1 AT03703141T AT03703141T ATE471371T1 AT E471371 T1 ATE471371 T1 AT E471371T1 AT 03703141 T AT03703141 T AT 03703141T AT 03703141 T AT03703141 T AT 03703141T AT E471371 T1 ATE471371 T1 AT E471371T1
Authority
AT
Austria
Prior art keywords
verotoxin
subunit
anticancer agent
attenuated
verotoxinvariants
Prior art date
Application number
AT03703141T
Other languages
English (en)
Inventor
Xiaoyan Liu
Original Assignee
Yoshida Hideo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yoshida Hideo filed Critical Yoshida Hideo
Application granted granted Critical
Publication of ATE471371T1 publication Critical patent/ATE471371T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03703141T 2002-02-04 2003-02-03 Antikrebsmittel mit verotoxinvarianten ATE471371T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002026577 2002-02-04
PCT/JP2003/001043 WO2003066854A1 (fr) 2002-02-04 2003-02-03 Agent anticancereux utilisant des variantes de verotoxines

Publications (1)

Publication Number Publication Date
ATE471371T1 true ATE471371T1 (de) 2010-07-15

Family

ID=27677819

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03703141T ATE471371T1 (de) 2002-02-04 2003-02-03 Antikrebsmittel mit verotoxinvarianten

Country Status (8)

Country Link
US (3) US20050163807A1 (de)
EP (1) EP1496116B1 (de)
JP (1) JP4214397B2 (de)
AT (1) ATE471371T1 (de)
AU (1) AU2003208097A1 (de)
DE (1) DE60333004D1 (de)
HK (1) HK1073130A1 (de)
WO (1) WO2003066854A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059382A1 (en) * 2005-09-09 2007-03-15 Board Of Regents, Univ. And Comm. College System Of Nevada... Medical treatment of breast cancer with boric acid materials
WO2009088403A2 (en) * 2007-10-08 2009-07-16 Rutgers, The State University Nontoxic shiga-like toxin mutant compositions and methods
WO2011022843A1 (en) * 2009-08-28 2011-03-03 The Hospital For Sick Children Use of a holotoxin to reduce endoplasmic reticulum-associated degradation of misfolded proteins
CN106217038A (zh) 2012-06-28 2016-12-14 环球仪器公司 灵活的装配机械、系统及方法
MX2015012808A (es) 2013-03-12 2016-05-31 Molecular Templates Inc Inmunotoxinas de union a cd20 para inducir internalizacion celular y metodos que usan las mismas.
CN106414483A (zh) 2014-01-27 2017-02-15 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
KR102139402B1 (ko) 2014-02-07 2020-07-29 유니버셜 인스트루먼츠 코퍼레이션 펌프와 모터를 구비한 픽앤드플레이스 헤드
EP3825327A1 (de) * 2014-03-11 2021-05-26 Molecular Templates, Inc. Proteine mit bindungsregionen, shiga-toxin-a-untereinheiteffektorregionen und carboxyterminale, endoplasmatische retikulumlokalisierungssignalmotive
EP3604333B1 (de) * 2014-03-11 2021-05-05 Molecular Templates, Inc. Proteine mit aminoterminalem proximalem shiga-toxin-a-untereinheiteneffektorregionen und auf zellen abgerichtete immunglobulinbindungsregionen, die cd38 spezifisch binden können
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
US10815469B2 (en) 2014-06-11 2020-10-27 Molecular Templates, Inc. Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties
US10392425B2 (en) 2015-02-05 2019-08-27 Molecular Templates, Inc. Multivalent CD20-binding molecules comprising Shiga toxin A subunit effector regions and enriched compositions thereof
AU2016271124C1 (en) 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
AU2016297920A1 (en) * 2015-07-26 2018-01-18 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin A subunit effectors and CD8+ T-cell epitopes
MX2019006656A (es) 2016-12-07 2019-09-09 Molecular Templates Inc Polipeptidos efectores de la sub-unidad a de la toxina shiga andamiajes de los efectores de la toxina shiga y moleculas con direccion hacia las celulas para la conjugacion especifica del sitio.
US10454114B2 (en) 2016-12-22 2019-10-22 The Research Foundation For The State University Of New York Method of producing stable, active and mass-producible Pt3Ni catalysts through preferential co etching
ES2971981T3 (es) 2017-01-25 2024-06-10 Molecular Templates Inc Moléculas de reconocimiento de células que comprenden efectores de la subunidad A de la toxina Shiga desinmunizados y epítopos de células T CD8+
CA3097178A1 (en) 2018-04-17 2019-10-24 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552144A (en) * 1992-01-22 1996-09-03 Microcarb, Inc. Immunogenic shiga-like toxin II variant mutants
CA2116179C (en) 1994-02-22 2008-01-08 C. A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
US5968894A (en) * 1994-02-22 1999-10-19 Lingwood; Clifford A. Verotoxin pharmaceutical compositions and medical treatments therewith
US5837680A (en) * 1996-02-16 1998-11-17 Children's Medical Center Corporation Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis
AU7348998A (en) * 1997-05-16 1998-12-08 Hospital For Sick Children, The Inhibition of angiogenesis by verotoxins

Also Published As

Publication number Publication date
AU2003208097A1 (en) 2003-09-02
EP1496116A1 (de) 2005-01-12
US20100047285A1 (en) 2010-02-25
JP4214397B2 (ja) 2009-01-28
DE60333004D1 (de) 2010-07-29
US20070154485A1 (en) 2007-07-05
US20050163807A1 (en) 2005-07-28
HK1073130A1 (en) 2005-09-23
EP1496116A4 (de) 2005-08-24
WO2003066854A1 (fr) 2003-08-14
JPWO2003066854A1 (ja) 2005-06-02
EP1496116B1 (de) 2010-06-16

Similar Documents

Publication Publication Date Title
HK1073130A1 (en) Anticancer agents using vero toxin variants
NZ593289A (en) Anti-neuropilin-1 antibodies for treating angiogenesis
DK1468014T3 (da) Sammensætninger og fremgangsmåder til WT1-specifik immunterapi
DK2014678T3 (da) KDR-peptider og vacciner indeholdende disse
NO20045354L (no) Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser
EP1498424A3 (de) Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
WO2004076644A3 (en) A composition for delivering an agent to a target cell and uses thereof
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2004080418A3 (en) Nucleic acid compounds for inhibiting angiogenesis and tumor growth
WO2004050707A3 (de) Tumorspezifische erkennungsmoleküle
WO2003013533A3 (en) Methods for improved treatment of cancer with irinotecan based on mrp1
EA200401525A1 (ru) Способы лечения гепатита (варианты )
DE602006014009D1 (de) Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs
DK1536006T3 (da) Cancerantigener og anvendelse deraf
ATE311476T1 (de) Polymorphismen im gen für den humanen organischen anionentransporter c (oatp-c)
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
RS20050577A (en) Compositions and methods for treating cancer using igsf9 and liv-1
ATE393170T1 (de) Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers
AU2003234342A8 (en) Ablated slam-dependent entry
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
WO2002101076A3 (en) Methods for targeted expression of therapeutic nucleic acid

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties